stoxline Quote Chart Rank Option Currency Glossary
Tekla Life Sciences Investors (HQL)
13.22  -0.22 (-1.64%)    05-28 16:00
Open: 13.44
High: 13.465
Volume: 94,198
Pre. Close: 13.44
Low: 13.19
Market Cap: 362(M)
Technical analysis
2024-05-28 4:53:25 PM
Short term     
Mid term     
Targets 6-month :  16.07 1-year :  16.69
Resists First :  13.76 Second :  14.28
Pivot price 13.84
Supports First :  12.9 Second :  10.74
MAs MA(5) :  13.55 MA(20) :  13.73
MA(100) :  13.65 MA(250) :  13.19
MACD MACD :  0 Signal :  0.1
%K %D K(14,3) :  2.8 D(3) :  17.1
RSI RSI(14): 37.9
52-week High :  14.36 Low :  11.34
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ HQL ] has closed below the lower bollinger band by 0.9%. Bollinger Bands are 55.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 13.55 - 13.68 13.68 - 13.76
Low: 12.91 - 13.08 13.08 - 13.19
Close: 13.03 - 13.3 13.3 - 13.47
Company Description

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Headline News

Fri, 24 May 2024
Tekla World Healthcare Fund Paid Distribution - The Globe and Mail

Wed, 22 May 2024
abrdn Announces Its Appointment to Four U.S. Specialist Healthcare Closed-End Funds, New Board of Trustees to the ... - The Globe and Mail

Wed, 22 May 2024
Tekla Life Sciences Investors Declares Distribution - The Globe and Mail

Thu, 21 Mar 2024
abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ ... - Kansas City Star

Sat, 16 Oct 2021
Healthcare Is About To Soar, And These 6%+ Dividends Will Profit - Forbes

Wed, 29 May 2024

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Financial Services
Asset Management
Shares Out 27 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 34.3 (%)
Shares Short 58 (K)
Shares Short P.Month 21 (K)
Stock Financials
EPS 0.79
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 16.12
Profit Margin 156.4 %
Operating Margin -48.8 %
Return on Assets (ttm) -0.4 %
Return on Equity (ttm) 1.2 %
Qtrly Rev. Growth 34.4 %
Gross Profit (p.s.) 0
Sales Per Share 0.12
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 16.73
PEG Ratio 0
Price to Book value 0.82
Price to Sales 103.01
Price to Cash Flow 0
Stock Dividends
Dividend 0.38
Forward Dividend 0
Dividend Yield 2.9%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android